Hunan Er-Kang Pharmaceutical Co (SZSE:300267) 5-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co 5-Year EBITDA Growth Rate?

Hunan Er-Kang Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.00.

During the past 12 months, Hunan Er-Kang Pharmaceutical Co's average EBITDA Per Share Growth Rate was -950.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -68.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hunan Er-Kang Pharmaceutical Co was 95.70% per year. The lowest was -68.70% per year. And the median was 22.55% per year.

Competitive Comparison of Hunan Er-Kang Pharmaceutical Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Er-Kang Pharmaceutical Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hunan Er-Kang Pharmaceutical Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Er-Kang Pharmaceutical Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Hunan Er-Kang Pharmaceutical Co's 5-Year EBITDA Growth Rate falls into.

Hunan Er-Kang Pharmaceutical Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Hunan Er-Kang Pharmaceutical Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331

Website

http://www.hnerkang.com

Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines